Analystreport

Fulcrum Therapeutics, Inc. (NASDAQ: FULC) was upgraded by analysts at HC Wainwright from a "neutral" rating to a "buy" rating.

Fulcrum Therapeutics, Inc.  (FULC) 
Last fulcrum therapeutics, inc. earnings: 3/5 07:00 am Check Earnings Report